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Inhibition of endogenous nitric oxide synthesis activates particulate
guanylyl cyclase in the rat renal glomeruli. Nitric oxide (NO) plays a
crucial role in the regulation of kidney function and metabolism. Our
previous study showed that dexamethasone, one of several known selective
inhibitors of inducible nitric oxide synthase (NOS), had a stimulatory
effect on soluble guanylyl cyclase in the glomeruli of rat kidney. However,
in the presence of dexamethasone, the atrial natriuretic factor (ANF)-
dependent system remained suppressed. The aim of the present study was
to investigate whether inhibition of synthesis of endogenous NO modu-
lates the activity of the guanylyl cyclase system(s) in glomeruli. In these
studies, rats were injected with a non-selective NOS inhibitor, N-w-nitro-
L-arginine methyl ester (NAME; NAME-group), or saline solution (con-
trols; C-group). Creatinine clearance (Ccr), and plasma and urinary
nitrate/nitrite (NO,) levels decreased in the NAME-group, but plasma
and urinary guanosine 3',5'—cyclic monophosphate (cGMP) contents were
unchanged. In the presence of 0.1 ANF, synthesis of cGMP in the
NAME-group exceeded threefold the cGMP production in the C-group.
In addition, the pre-contracted glomeruli of the NAME-group were fully
relaxed at 0.1 LM ANF, but glomeruli obtained from the C-group were
relaxed in the presence of a 10 times higher dose of ANF. The increased
sensitivity of glomeruli to ANF was possibly due to the more than doubled
activity of particulate guanylyl cyclase (pGC) in the NAME-group in
comparison with the C-group. In the presence of 100 jrM sodium nitro-
prusside (SNP), soluble guanylyl cyclase (sGC) generated significantly
lower cGMP production in the NAME-group than in the C-group (1.61
0.33 vs. 2.91 0.69 nmol/mg protein/lO mm, respectively). These results
demonstrate that inhibition of the synthesis of endogenous NO may also
have an inhibitory effect on the activity of sGC. In addition, increased
activity of the pGC and ANF-dependent system appears to be compen-
satory to the altered activity of soluble guanylyl cyclase.
sis of endogenous NO are controversial; for example, either
decreased or unchanged glomerular filtration rates (GFR) have
been observed [5—8].
Glucocorticoids are known to cause hyperfiltration and an
increase in diuresis. In addition, they are potent and selective
inhibitors of inducible nitric oxide synthase (NOS) [10]. Results
obtained in our laboratory on the isolated kidney glomeruli
showed that in dexamethasone-treated rats both sensitivity and
activity of NO-dependent processes were markedly increased,
whereas the ANF-stimulated cGMP synthesis was suppressed [9].
Enhanced sensitivity to the sodium nitroprusside (SNP) shown in
our previous study was interpreted to be an up-regulation of the
receptor coupled with an enzyme resulting from the inhibition of
the endogenous NO synthesis. It was reported that elimination of
NO-mediated vasodilation could generate a supersensitivity to
nitrovasodilators in vascular rings [11—13]. The purpose of this
study was to investigate whether inhibition of synthesis of NO in
vivo (i) modulates the response of the isolated glomeruli to
exogenous NO, and (ii) affects the ANF-dependent system in rat
kidney. The animals were treated with nonselective inhibitor of
NOS, N-w-nitro-L-arginine methyl ester (NAME), and the activ-
ity of the cGMP-generating system and the ability of isolated
glomeruli to relaxation were evaluated.
METHODS
Animals and tissue samples
Nitric oxide (NO) and atrial natriuretic factor (ANF) are the
main relaxation factors functioning in the kidney by stimulation of
the synthesis of cyclic guanylic acid (cGMP). Endogenous NO
plays an important role in the regulation and maintenance of
renal hemodynamics and electrolyte balance [1, 21. The function
of renal glomeruli also appears to be affected by NO, and
co-localization of the NO synthases and the soluble guanylyl
cyclase (sGC) has been identified [1—4], However, data charac-
terizing kidney function under the conditions of inhibited synthe-
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Male Wistar rats (180 to 250 g) were fed with standard diet and
had a free access to tap water. Three days before beginning the
study (—3-day), rats were placed in metabolic cages. Starting at
—i-day, animals were injected three times (every 12 hr) with
either N-w-nitro-L-arginine methyl ester (NAME; s.c., 40 mg/kg)
or with an equal volume of saline solution (NAME- and C-groups,
respectively). Urine collection (24 hr) was initiated at the time of
the first injection of the NAME or saline solution. The blood
collection from the abdominal aorta and excision of the kidneys
were done one hour after the third injection. Plasma and urine
samples were stored at _2OeC.
Net urinary excretion of hydrogen ion
The pH of the urine was measured immediately after collection.
Titratable acidity was evaluated from the amount of 0.1 msi
NaOH used for titrating the sample containing 0.1 ml urine, 0.9
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ml H20, and 0.4 ml 0.1 N HCI up to pH 7.42. Ammonia ions were
determined using the formalin titrimetric method [14].
Isolation of the kidney glomeruli
One NAME and one C rat were used in each experiment, and
each experiment was repeated several times (N = 9 for in vivo
experiments, N = 6 for experiments with the intact glomeruli, and
N = 5 for experiments with guanylyl cyclases). The kidneys were
excised and placed in the ice-cold PBS, pH 7.4. Glomeruli were
isolated by the gradual sieving technique, as described previously
[9]. The final preparation consisted of decapsulated glomeruli
without arterioles; tubular contamination was assessed to be
< 6%. The entire procedure was carried out in the ice bath and
took approximately two hours.
Synthesis of cGMP in isolated glomeruli
The method of evaluating the capability of isolated glomeruli
(in suspension) to produce cGMP was described earlier [9].
Briefly, a suspension containing 6,000 glomeruli/450 .d PBS
supplemented with 1 mi 3-isobutyl-1-methylxantine (IBMX), 75
U superoxide dismutase (SOD) and 5 mrvi cysteine for incubations
with SNP was preincubated for 10 minutes at 37°C. Incubation
was initiated by addition of SNP or ANF (c.f. 0.01 to 100 jiM, and
0.01 to 1.0 jiM, respectively) to the suspension, and then stopped
two minutes later by the introduction of 30% HCIO4 to the
medium. The above procedure was performed in glomeruli iso-
lated from both the NAME- and C-group rats. In an additional
series of experiments, glomeruli isolated from the C-group were
preincubated for 10 minutes with NAME (cf. 1 jiM) prior to the
addition of ANF in order to initiate incubation.
Isolation of soluble and particulate isoforms of guanylyl cyclase
(sGC and pGC, respectively)
The procedure was carried out as described previously [15, 16].
Briefly, =40,000 freshly isolated glomeruli were sonicated for two
minutes in ice-cold buffer containing (in mM): 50 Tris-HC1 (pH
8.2), 250 sucrose, 1 EDTA-Na2, I 1,4-dithiothreitol, 0.1 phenyl-
methylsulfonyl fluoride (PMSF). After one hour of centrifugation
(100,000 g; 4°C), the supernatant was frozen and stored in liquid
nitrogen for determinations of the activity of sGC. The remaining
pellet was sonicated for 30 seconds in washing buffer A (in mM):
500 KCI, 50 Tris-HCI (pH 8.2), 1 EDTA-Na2, II ,4-dithiothreitol,
and 0.1 PMSF. After 30 minutes of centrifugation (100,000 ><
the pellet was sonicated for 30 seconds in washing buffer B (that
is, buffer A without KCI). Centrifugation was repeated, and finally
the pellet was suspended in 1.4 ml of homogenizing buffer and
stored in liquid nitrogen for measurements of the activity of pGC.
Determinations of the activity of sGC and pGC
Samples containing 15 to 20 jig protein were preincubated for
five minutes (water bath at 37°C) in 500 p.1 of medium containing
(in mM) 20 Tris-HCI (pH 7.6), 1 IBMX, 15 creatine phosphate,
and 5 U of creatine phosphokinase; SNP or ANF were added to
the medium at various concentrations. Reaction was started by
addition of 1 mivi GTP and 4 mrvt MgCl2 to each tube, and stopped
10 minutes later by the addition of 100 p.! of ice-cold HCIO4
(30%); samples were neutralized with 5 N KOH and 5 N K2C03,
















mmol X 24hr' ><
IOOgbodywt'
C-group 223 10 5.8 0.7 0.67 0.05 0.88 0.10 0.92 0.11
NAME- 233 10 6.7 0.5 0.45 O.03a 0.82 0.07 0.83 0.06
group
cGMP assay
cGMP was determined by a previously described radioimmu-
noassay with some modifications [17]. Rabbit anti-cGMP antibod-
ies (prepared in our laboratory) and [8, 5'-3HJ cGMP were
employed. Radioactivity was determined in duplicates by the
liquid scintillation counting method (Beckman LS 5801).
NOX assay in plasma and urine
The total NOX (that is, NO2 and NO3) content was measured
as described previously [18—21]; nitrate was reduced to nitrite with
nitrate reductase and then the nitrite content was determined
according to the Griess reaction. Briefly, 50 jil of medium
containing 0.1 M potassium-phosphate buffer (pH 7.5), 5 p.M FAD,
0.3 jiM NADPH, and 80 p.U nitrate reductase was added to 75 p.!
of urine or 75 p.1 of deproteinized plasma sample. Reaction tubes
were incubated for 60 minutes at the room temperature, and then
the reaction was terminated by heating the samples in boiling
water for three minutes. Reaction mixtures were incubated (20
mm, room temperature) with 625 p.1 of the Griess reagent.
Absorbance (548 nm) was recorded for each sample.
Glomerular inulin space
Glomerular inulin space (GIS) was measured according to a
previously described method [22, 23]. Immediately after isolation,
=2,00() glomeruli were suspended in 200 p.! PBS containing 1%
bovine serum albumin (BSA) and 0.5 p.Ci [3H]-inulin. Samples
were preincubated in water bath (37°C, 30 mm). The five minute
incubation was initiated by addition of 50 p.! of Ang II in PBS (c.f.,
1 p.M) or 50 p.! of Ang II combined with varying concentrations of
SNP or ANF. Then 200 j.d of suspension were transferred to the
microtube containing 100 jil of the ice-cold silicone oil (AR2O)
and centrifuged briefly (5,000 g; 4°C). Next, glomeruli were spun
through the oil (medium remained on the surface). Tips of the
vials containing pellets of glomeruli were cut off and the content
was suspended in 500 p.! of Triton X-100 (0.3%) for two hours.
After the pellets were solubilized, 2 ml of scintillation cocktail
were added, and samples were left overnight at the room temper-
ature. Supernatant (50 p.1) was treated in an identical manner.
Radioactivity of samples (triplicates) was measured by liquid
scintillation counting. The inulin space of a single glomerulus
(pi/glomerulus) was computed as follows:
GIS (pi/glomerulus) =
3H-pellet(cpm) 1
3H-supematant(cpm/pl) Number of glomeruli
Table 1. Effect of NAME on rat kidney function parameters
Abbreviations are: body wt, body weight; C, creatinine clearance.
Values are mean 5E, N 9.









































































































Control NAME Control NAME
Fig. 1. Effect of NAME on the level of plasma
NO (A), cGMP levels (B), urinary excretion
of NO (C), and cGMP (D); N = 9.
Other analyses
Sodium and creatinine concentrations in urine and plasma were
determined using standard clinical laboratory methods. Protein
content was determined by the method of Lowiy or BCA using
BSA as standards for both procedures [24, 25].
Calculations and statistics
Results are expressed as the mean SE (N = 5 for each group
under various conditions). Statistical analyses were done using
Mann-Whitney test; P < 0.05 was considered to be statistically
significant.
Materials
NAME, IBMX, phenylmethylsulfonyl fluoride (PMSF), SOD,
GTP, 3',5'- cGMP, FAD and angiotensin 11 (Ang II) were
obtained from Sigma Chemical Co. (St. Louis, MO, USA). Nitrate
reductase was purchased from Boehringer (Mannheim, Germa-
ny), [3H1-inulin from Amersham Life Science (Little Chalfont,
UK), and 3',5' [8, 5'-3H] cGMP from DuPont NEN Products
(Boston, MA, USA). ANF (human, 28 amino acids) was obtained
from Peninsula Laboratories Inc. (Belmont, CA, USA), and
creatine phosphate and phosphocreatine kinase from Caihiochem
AG (La Jolla, CA, USA). DTF was purchased from Carl Roth
(Karlsruhe, Germany) and silicone oil AR 20 from Salben-
Wacker-Chemie GmbH (Muenchen, Germany). All chemicals
were of the highest purity grade commercially available.
RESULTS
Effect of NAME on kidney function parameters
As shown in Table 1, in both the C and NAME group diuresis,
sodium and hydrogen ion excretion were similar. However,
NAME injection reduced Cr by about 30% (P < 0.05). In
addition, a twofold decrease in plasma NO0 level and urinary
excretion of N00 was observed in NAME- versus C-groups (Fig.
1 A and C, respectively). Plasma cGMP concentration and urinary
excretion of cGMP were unchanged in NAME-rats (Fig. I B and
D, respectively). These differences in NO and cGMP levels (that
is, reduced and unaffected, respectively) in response to NAME
administration suggest that there are compensatory alterations in
the activity of the cGMP-gencrating system.
Effect of NAME on cGMP synthesis in isolated renal glomeruli
Exposure of glomeruli isolated from the NAME-group to the
increasing concentrations of SNP (0.01 to 100 ILM) did not change
their ability to generate cGMP as compared to the C-group (Fig.
2A). However, in the presence of 0.1 p.M ANF, production of
cGMP by NAME-group glomeruli exceeded threefold those of'
the C-group (10.4 2.0 vs. 3.0 1.4 pmol/mg protein/2 mm,
respectively), as shown in Figure 2B. The peak of the synthesis of
cGMP in both groups was observed in the presence of I p.M ANF,
and at this concentration of ANF cGMP production was twice as
high in the NAME- than in the C-group (Fig. 2B). In contrast,















C-group group C-group group
Basal
—
0.35 0.06 0.61 0.lOa
-
0.18 0.03 0.13 0.04
SNP, 100 3.22 0.72k 2.23 0.43 0.18 0.04 0.19 0.05
/LM
ANF, 0.1 — — 0.49 0.05 0.83 0.18'
tLM
ANF, 1.0 0.20 0.10 0.25 0.20 — —
/.LM
glomeruli isolated from control rats and then incubated in the
presence or absence of 1 jIM NAME in medium produced cGMP
at the same rate in response to 1 LM ANF (15.1 2.5 and 13.3
2.0 pmol/mg protein/2 mm of cGMP, respectively). Therefore,
these results suggest a possible secondary effect of NAME on
ANF-dependent cGMP synthesis in glomeruli isolated from
NAME-rats, since ANF-stimulated cGMP production in glomer-
uli isolated from C-rats, which were incubated with or without
NAME, was similar. Thus, it is likely that inhibition of the
synthesis of endogenous NO triggered an increase in the activity
of ANF-dependent cGMP generating system in the NAME-
group.
Effect of NAME on the activity of sGC and pGC
The next series of experiments was designed to evaluate
whether altered cGMP production in NAME-group glomeruli
was preserved by cytosolic and/or membrane-bound guanylyl
cyclases. Therefore, production of cGMP by isolated isoforms of
the enzyme in response to addition of ANF and SNP to the media
was determined. As shown in Table 2, the addition of 100 jIM SNP
or 0.1 jIM ANF significantly increased the rate of cGMP synthesis
in respective cellular fractions in comparison to the basal rate in
both the C- and NAME-groups. Also, the rate of cGMP produc-
tion in particulate (membrane-bound, pGC) fraction was almost
twice as high in the NAME-group than in the C-group in response
to 0.1 jIM ANF. A lack of stimulatory effect of ANF (1.0 jIM) in
soluble fraction (sGC) as well as of SNP in pGC indicated that
preparations were not cross-contaminated.
In NAME-group preparations activities of both sGC (Fig. 3A)
and pGC (Fig. 3B), measured as a rate of cGMP production, were
significantly altered. In the cytosolic fraction of the NAME-group,
an addition of 100 jIM SNP significantly decreased the rate of
cGMP synthesis compared to the C-group (1.61 0.33 vs. 2.91
0.69 nmol/mg protein/lU mm, respectively; Fig. 3A). The stimu-
latory effect of ANF employed at various concentrations on the
activity of pGC was observed in both groups, but enzyme activity
was higher in the NAME-group than in the C-group. In the
presence of 0.1 /.LM ANF, the most effective concentration, the
rate of cGMP production was 0.69 0.17 and 0.33 0.07
nmol/mg protein/b mm in the NAME- and C-groups, respec-
tively.
Effect of NAME on SNP- and ANF-evoked relaxation of
glomeruli
To answer the question whether NAME-generated changes in
the rate of cGMP production are parallel to the relaxation of
glomeruli, the intracapillary volume of the isolated glomeruli
(glomerular inulin space, GIS) in response to various concentra-
tions of SNP and ANF was determined. Basal GIS of the
glomeruli in C- and in NAME-groups were similar (692 48 and
725 64 pl/glomerulus, respectively). As shown in Figure 4, the
addition of I jIM Ang II to the medium (without either SNP or
ANF) generated shrinkage of glomeruli in both groups, although
the reduction of volume was significantly less pronounced in the
NAME-group than the C-group (—51 6 vs. —73 10 p1/
glomerulus, respectively). Subsequent incubation of glomeruli in
the presence of different concentrations of SNP did not have a
relaxing effect on NAME-group glomeruli (Fig. 4A). However,
relaxation progressively increased in C-group glomeruli which were
exposed to 10 jIM SNP; glomeruli reached the initial volume at 100
jIM concentration (Fig. 4A). NAME-glomeruli were fully relaxed by
the addition of 0.1 jIM ANF in the presence of I jIM Ang II (Fig. 4B);
however, at this concentration ANF had no relaxing effect on
C-glomeruli. In the C-group, complete relaxation of glomeruli was
observed only in the presence of 1.0 jIM ANF.
DISCUSSION
Results of the present study indicate that in vivo administration
of NO synthase inhibitor, NAME, leads to the increased sensitiv-















Table 2. Activities of soluble and particulate guanylyl cyclase (sGC and
pGC, respectively) in glomeruli
Fig. 2. EWect of NAME on SNP (A) or ANF
stimulated (B) cGMP production in rat kidney
glomeruli isolated from the C-group (LI) and
the NAME-group (t). N = 6. P < 0.02 and
**p < 0.005, NAME-group versus C-group.
Values are mean SE, N = 5.
aP < 0.05, NAME-group vs. C-group for each enzyme
5P < 0.05, SNP or ANF vs. basal rate
U


































Fig. 4. Effect of NAME on glomeruli relaxation measured as the glomer-
ular inulin space (GIS) in the presence of a combination of Ang 11(1 LM)
with various concentrations of SNP (A) or Aug LI (1 M) with various
concentrations of ANF (B). Results are expressed as a GIS decrease from
the basal volume () in the C-group (0) and in NAME-group (•); N5 *p < 0,05 and **p < 0.01, NAME-group versus C-group.
2). In the presence of ANF in incubation medium, the ability of
NAME-glomeruli to synthesize cGMP and to relaxation was
enhanced.
Administration of NAME did not alter rat kidney function with
one exception: C'r was reduced, which is in agreement with previous
observations [5, 6]. However, diuresis and urinary excretion of
sodium and hydrogen ions were unchanged. These results indicate
that despite reduced GFR the basic kidney function was main-
tained in the NAME-group rats. The level of urinary and plasma
metabolites of NOX was significantly decreased, but cGMP
concentration in plasma and urine was unaffected in the NAME-
group as compared to the C-group (Fig. 1 A, B). Therefore, it
seems likely that reduced availability of endogenous NO may
result in the compensatory acceleration of cGMP synthesis.
Activation of sGC- and/or pGC-dependent system(s) resulting in
the increased rate of cGMP production is possible.
Kidney glomeruli possess receptors for two relaxatory factors:
NO and ANF [2, 26, 27]. As shown in this study, administration of
NAME over a 24 hour period affected both NO- and ANF-
receptors in rat kidney. Activation of the AN F-sensitive system in
the NAME-group was confirmed by the stimulation of cGMP
production (Fig. 2B) and also by the increased ability of glomeruli
to relax (Fig. 4B). However, an increased activity of the isolated
enzyme, pGC, in both the C- and NAME-groups provided
additional evidence for the activation of cGMP-generating system
by NAME (Fig. 3B). Surprisingly, the NO-dependent system
seemed to be suppressed at the same time. This was particularly
visible in the experiments in which glomeruli from NAME-group
incubated with 1 tM Ang II were insensitive to the relaxing action
of 100 jiM SNP (Fig. 4A). Activity of isolated sGC was also
decreased in the presence of SNP (100 jiM) in NAME-prepara-
tions, as shown in Figure 3A.
The observation that administration of NAME affected the
ANF-dependent system in the glomeruli and that the effect was
preserved in the isolated enzyme (that is, isoforms of guanylyl
cyclasc) suggests that changes in activity or sensitivity were due to
permanent structural changes. This phenomenon could be ex-
plained in two ways: one is that inhibition of NO synthesis may
induce an up-regulation of ANF receptors coupled with the
guanylyl cyclase, and the other is a down-regulation of the
clearance receptors. The latter hypothesis may he supported by
the observation that dexamethasone administered in vivo in-
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Fig. 3. Effect of NAME on the activity of sGC
(A) and pGC (B) in rat renal glomeruli isolated
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receptors for ANF [28]. However, currently a relationship be-
tween NO inhibition and the density/affinity of GC-bound natri-
uretic peptide receptors in glomeruli is unknown.
The effect of NAME on the production of cGMP was parallel
to the altered ability of glomeruli to relax in the presence of SNP
and ANF. However, glomeruli from the NAME-group rats ap-
peared to be significantly less susceptible to the contracting effect
of Ang II. This phenomenon could be explained by increased
basal sGC activity in the NAME-group (Table 2), counteracting
the action of Ang II. Surprisingly, SNP added to the medium was
not able to reverse even such an attenuated contraction (Fig. 4A).
This discrepancy may be partially explained by the decreased
activity of sGC in glomeruli from the NAME-group (Fig. 3A).
Decreased activity of the NO-dependent system in the NAME
glomeruli is inconsistent with earlier reports. It was shown that
inhibition of synthesis of NO or removal of arterial endothelium
contributed to the development of hypersensitivity to NO [11—13].
However, these responses were observed in the shorter experi-
ments, up to one hour. In our experiments, rats were injected with
NAME three times during a 24 hour period.
In conclusion, we have shown that in vivo inhibition of endog-
enous synthesis of NO increased the activity/sensitivity of the
renal ANF-dependent guanylyl cyclase system. At the same time,
activity of the NO-dependent sGC-system was suppressed. This
phenomenon may explain, at least in part, the current observation
that despite evident suppression of endogenous NO synthesis, the
cGMP level in plasma and its urinaly excretion was unchanged.
Therefore, we conclude that in response to blockade of endogenous
NO synthesis, a compensatoly ANF-dependent, cGMP-generating
system is activated and/or sensitized. However, the questions regard-
ing mechanism(s) and the sequence of events of the observed
reciprocal relationship between both relaxation systems in kidney
glomeruli remain unanswered [29]. While the function of the kidney
glomeruli is strictly controlled by the interaction of the contracting
and relaxing systems, our observations imply that the relaxing system
in turn contributes to the maintenance of a stable level of their
common second messenger, cGMP.
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